Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.730
-0.090 (-4.95%)
At close: Nov 6, 2025, 4:00 PM EST
1.730
0.00 (0.00%)
After-hours: Nov 6, 2025, 8:00 PM EST
Lineage Cell Therapeutics Revenue
Lineage Cell Therapeutics had revenue of $2.77M in the quarter ending June 30, 2025, with 96.38% growth. This brings the company's revenue in the last twelve months to $10.91M, up 76.43% year-over-year. In the year 2024, Lineage Cell Therapeutics had annual revenue of $9.50M with 6.19% growth.
Revenue (ttm)
$10.91M
Revenue Growth
+76.43%
P/S Ratio
36.83
Revenue / Employee
$141,740
Employees
77
Market Cap
395.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.50M | 554.00K | 6.19% |
| Dec 31, 2023 | 8.95M | -5.76M | -39.16% |
| Dec 31, 2022 | 14.70M | 10.36M | 238.70% |
| Dec 31, 2021 | 4.34M | 2.52M | 137.73% |
| Dec 31, 2020 | 1.83M | -1.69M | -48.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LCTX News
- 4 hours ago - Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 7 days ago - Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - Business Wire
- 7 weeks ago - Lineage Cell Therapeutics, Inc. (LCTX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript - Seeking Alpha
- 2 months ago - Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes - Business Wire
- 2 months ago - Lineage Cell Therapeutics to Present at September 2025 Investor Conferences - Business Wire
- 2 months ago - Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss - Business Wire
- 3 months ago - Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire